Acquista Criptovalute
Paga con
USD
USD
Buy & Sell
Hot
Supports Visa, MasterCard, SEPA & more
P2P
0 Fees
Flexible trading, zero fees
Gate Card
Use your crypto for payments worldwide
Mercati
Trading
Basic
Advanced
Futures
Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Opzioni
Hot
Trade European-style Vanilla Options
Conto unificato
Massimizza l'efficienza del tuo capitale
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Guadagna
Lancia
CandyDrop
tag
Raccogli le caramelle per guadagnare airdrop
Launchpool
Staking rapido, guadagna potenziali nuovi token
HODLer Airdrop
Fai holding GT e ottieni enormi airdrop gratuitamente
Launchpad
Sii tra i primi per il prossimo grande progetto
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Investimento
Square
Square
Post, share, and explore crypto trends
Live
moments live
Live crypto market analysis
Chat
Chat with crypto traders
News
What is happening in crypto
flower_head
Altro
Promozioni
AI
Altro
TradFi
Rewards
JNJ

Prezzo Johnson & Johnson

Closed
JNJ
$238,41
-$2,56(-1,06%)

*Data last updated: 2026-04-08 00:42 (UTC+8)

As of 2026-04-08 00:42, Johnson & Johnson (JNJ) is priced at $238,41, with a total market cap of $574,54B, a P/E ratio of 18,80, and a dividend yield of 2,18%. Today, the stock price fluctuated between $236,12 and $240,78. The current price is 0,96% above the day's low and 0,98% below the day's high, with a trading volume of 4,75M. Over the past 52 weeks, JNJ has traded between $146,11 to $251,71, and the current price is -5,28% away from the 52-week high.

JNJ Key Stats

Yesterday's Close$240,97
Market Cap$574,54B
Volume4,75M
P/E Ratio18,80
Dividend Yield (TTM)2,18%
Dividend Amount$1,30
Diluted EPS (TTM)11,03
Net Income (FY)$26,80B
Revenue (FY)$94,19B
Earnings Date2026-04-14
EPS Estimate2,69
Revenue Estimate$23,59B
Shares Outstanding2,38B
Beta (1Y)0.329
Ex-Dividend Date2026-02-24
Dividend Payment Date2026-03-10

About JNJ

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
SectorHealthcare
IndustryDrug Manufacturers - General
CEOJoaquin Duato
HeadquartersNew Brunswick,NJ,US
Official Websitehttps://www.jnj.com
Employees (FY)138,20K
Average Revenue (1Y)$681,57K
Net Income per Employee$193,95K

Johnson & Johnson (JNJ) FAQ

What's the stock price of Johnson & Johnson (JNJ) today?

x
Johnson & Johnson (JNJ) is currently trading at $238,41, with a 24h change of -1,06%. The 52-week trading range is $146,11–$251,71.

What are the 52-week high and low prices for Johnson & Johnson (JNJ)?

x

What is the price-to-earnings (P/E) ratio of Johnson & Johnson (JNJ)? What does it indicate?

x

What is the market cap of Johnson & Johnson (JNJ)?

x

What is the most recent quarterly earnings per share (EPS) for Johnson & Johnson (JNJ)?

x

Should you buy or sell Johnson & Johnson (JNJ) now?

x

What factors can affect the stock price of Johnson & Johnson (JNJ)?

x

How to buy Johnson & Johnson (JNJ) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

JNJ
CFD
Fai trading

Hot Posts su Johnson & Johnson (JNJ)

SelfRugger

SelfRugger

1 ore fa
This is a paid press release. Contact the press release distributor directly with any inquiries. Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer ===================================================================================================================================================== PR Newswire Fri, February 27, 2026 at 4:30 AM GMT+9 8 min read In this article: JNJ -1.00% _Combination demonstrates deep PSA responses and favorable safety profile with plans to advance into Phase 3_ _Data highlight the potential of this first-in-class next-generation T-cell engager to expand the role of immunotherapy in prostate cancer_ RARITAN, N.J., Feb. 26, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced preliminary results from a Phase 1b study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific T-cell engaging antibody, in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. The combination demonstrated a safety profile consistent with docetaxel alone, with no new or unexpected safety signals observed. The regimen also showed clinically meaningful efficacy, including high rates of prostate-specific antigen (PSA) responses and sustained PSA reductions, supporting continued development and advancement into Phase 3 studies. The results were presented for the first time at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (Abstract #171).1 (PRNewsfoto/Johnson & Johnson) Pasritamig is designed to engage the immune system through a novel mechanism of action, binding CD3 on T cells and human kallikrein 2 (KLK2). KLK2 is a novel, highly specific prostate cancer target with minimal expression outside prostate tissue. By both activating and directing T cells to KLK2-expressing tumor cells, pasritamig enables targeted immune engagement. This differentiated, prostate-specific approach was intentionally built to focus immune activity on prostate cancer cells, which may help limit effects on healthy tissue, and supports administration in a doctor's office rather than hospital setting. "These data represent an important step forward for patients with advanced prostate cancer," said Professor Shahneen Sandhu,* M.D., Ph.D., MBBS, FRACP, Associate Professor, Consultant Medical Oncologist and researcher at Peter MacCallum Cancer Centre, and study investigator. "In a disease where outcomes remain poor for many patients, seeing encouraging clinical activity alongside a favorable safety profile in combination with docetaxel reinforces the potential of this approach and supports further clinical development." "Based on these findings, we are increasingly confident in the potential of pasritamig to meaningfully improve outcomes for people with prostate cancer," said Charles Drake, M.D., Ph.D., Vice President, Prostate Cancer and Cross Cancer Immuno-Oncology, Johnson & Johnson. "The ability to combine pasritamig with docetaxel, where prior approaches in the field have fallen short, gives us a strong foundation for Phase 3 development. What we're seeing with this combination, including deep and durable PSA responses, underscores the promise of this combination immunotherapy approach and our commitment to advancing innovation that can make a difference for patients." La historia continúa **Detailed Study Results** In the study, pasritamig was evaluated in combination with docetaxel in an outpatient setting in patients with metastatic castration-resistant prostate cancer whose disease had progressed following androgen receptor pathway inhibitor therapy. Approximately half of the patients (45 percent) had received at least one prior taxane-based regimen. The primary endpoint was safety and identification of the recommended regimen for further development in Phase 2/3 studies, with secondary and exploratory endpoints assessing clinical activity, including PSA response rates.1 As of December 9, 2025, 51 patients had received pasritamig plus docetaxel, including patients who were pretreated with a median of three prior therapies (range, 1-9). Reductions of 50 percent or greater in PSA levels were achieved in 64.7 percent of patients overall and in 75.0 percent of taxane-naïve patients. Reductions of 90 percent or greater in PSA levels were achieved in 39.2 percent of patients overall and 53.6 percent of taxane-naïve patients. Among taxane-naïve patients with bone-only disease, confirmed PSA reductions of 50 percent or greater and 90 percent or greater were observed in 88.2 percent and 76.5 percent of patients, respectively. Patients were able to continue pasritamig beyond docetaxel discontinuation. Those patients received a median of six docetaxel doses every three weeks and eight pasritamig doses every six weeks, supporting the potential for sustained disease control over time.1 The safety profile of pasritamig plus docetaxel was consistent with the known safety profile of docetaxel in metastatic castration-resistant prostate cancer. The most common treatment-related adverse events (TRAEs) occurring in at least 20 percent of patients included fatigue (60.8 percent), alopecia (41.2 percent), diarrhea and nausea (31.4 percent each), peripheral edema (27.5 percent), peripheral sensory neuropathy (25.5 percent) and dysgeusia (23.5 percent). Pasritamig-related adverse events occurring in at least 10 percent of patients were fatigue (33.3 percent) and non-chronic diarrhea (11.8 percent). Grade 3 or higher TRAEs attributed to docetaxel were observed in 29.4 percent of patients, compared with only two percent attributed to pasritamig. No patients experienced cytokine release syndrome of any grade or treatment-related deaths.1 Two ongoing Phase 3 studies are evaluating pasritamig in the metastatic castration-resistant prostate cancer setting. KLK2-comPAS (NCT07164443) is evaluating pasritamig as monotherapy, and KLK2-PASenger (NCT07225946) is evaluating pasritamig in combination with docetaxel.2,3 Beyond these Phase 3 studies, pasritamig is also being evaluated in earlier-phase combination studies. Pasritamig monotherapy has received Breakthrough Therapy Designation in China and Fast Track designation from the U.S. Food and Drug Administration, supporting its continued clinical development. **About the Study** The Phase 1b study (NCT05818683) is an open-label trial evaluating the safety and clinical activity of pasritamig in combination with docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed following treatment with an androgen receptor pathway inhibitor. The primary objective is to determine the recommended regimen for further development based on safety, with secondary and exploratory endpoints assessing clinical activity. Pasritamig was administered intravenously every six weeks, with initial step-up doses given during the first treatment cycle, in combination with docetaxel administered intravenously every three weeks. Treatment was delivered in an outpatient setting. Corticosteroids were used only as standard premedication for docetaxel, and hematopoietic growth factor support was permitted as needed.4 **About Pasritamig (JNJ-78278343)** Pasritamig (JNJ-78278343) is an investigational T-cell-redirecting bispecific antibody (bsAb) targeting human kallikrein 2 (KLK2) on prostate cancer cells and CD3 receptor complexes on T cells, leveraging the body's immune system to selectively target and eliminate cancer cells. This innovative approach is being evaluated in pretreated patients with metastatic castration-resistant prostate cancer (mCRPC), a patient population with limited treatment options. **About Metastatic Castration-Resistant Prostate Cancer (mCRPC)** Metastatic castration-resistant prostate cancer (mCRPC) is a challenging and aggressive stage of prostate cancer where the disease progresses despite androgen deprivation therapy.5 Patients often experience metastasis to bones and lymph nodes, leading to poor outcomes and limited treatment options, including chemotherapy and second-line hormone therapies.6 The median overall survival ranges from 13.5 to 31.6 months depending on the site of metastasis, with a typical range of 15 to 36 months across the broader population.7,8 Survival rates can vary significantly depending on factors such as prior treatment history, disease burden, and response to therapy. The need for more effective treatments is critical, as the disease continues to impact a large number of men globally, with metastatic castration-resistant prostate cancer (mCRPC) being responsible for a substantial number of prostate cancer-related deaths. **About Johnson & Johnson** At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more at at www.innovativemedicine.jnj.com. Follow us at @JNJInnovMed. **Cautions Concerning Forward-Looking Statements** _This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of pasritamig (JNJ-78278343). The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at __www.sec.gov__, __www.jnj.com_ _or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments._ *Professor Shahneen Sandhu, M.D., Ph.D., MBBS, FRACP has provided consulting, advisory, and speaking services to Johnson & Johnson; she has not been paid for any media work. Source: Johnson & Johnson | ______________________ | | --- | | 1 Patel MR, et al. Safety and Efficacy of Pasritamig (PAS) + Docetaxel (DOCE) in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC): Initial Results of a Phase 1b Study. Presented at: 2026 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium; February 26, 2026; San Francisco, California. | | 2 ClinicalTrials.gov. A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) (KLK2-comPAS). Accessed February 2026. | | 3 ClinicalTrials.gov. A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (KLK2-PASenger). Accessed February 2026. | | 4 ClinicalTrials.gov. A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer. Accessed February 2026. | | 5 Kushwaha PP, Gupta S. New insights for drug resistance in metastatic castration-resistant prostate cancer. Cancer Drug Resist. 2022;5(3):846-849. Published 2022 Aug 2. doi:10.20517/cdr.2022.83 | | 6 Wallace K, Landsteiner A, Bunner S, Engel-Nitz N, Luckenbaugh A. Epidemiology and mortality of metastatic castration-resistant prostate cancer (mCRPC) in a managed care population in the United States. J Clin Oncol. 2020;38(15_suppl):e13592. doi:10.1200/JCO.2020.38.15_suppl.e13592 | | 7 Wallace KL, Landsteiner A, Bunner SH, Engel-Nitz NM, Luckenbaugh AN. Increasing prevalence of metastatic castration-resistant prostate cancer in a managed care population in the United States. Cancer Causes Control. 2021;32(12):1365-1374. doi:10.1007/s10552-021-01484-4 | | 8 Kawahara T, Saigusa Y, Yoneyama S, et al. Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide. BMC Cancer. 2023;23:214. doi:10.1186/s12885-023-10700-0 | | **Media contact:** Oncology Media Relations oncology_media_relations@its.jnj.com  | **Investor contact: **Jessica Margevich investor-relations@its.jnj.com | | --- | --- | | | | | | **U.S. Medical Inquiries** | | | +1 800 526-7736 | Cision View original content to download multimedia: Condiciones y Política de privacidad Privacy Dashboard More Info
0
0
0
0
CoffeeNFTs

CoffeeNFTs

4 ore fa
As the Dow Jones Industrial Average and other stock indexes traded off their lows during Tuesday's session, **Johnson & Johnson** (JNJ), **AstraZeneca** (AZN), **Burlington Stores** (BURL) and **TJX** (TJX) were among the best names to watch in the currently volatile market. With key indexes trying to rebound from heavy losses in recent sessions, however, investors using The IBD Methodology await exceptional breakouts past correct buy points, while playing defense as they watch for sell signals. ↑ X This video file cannot be played.(Error Code: 102630) Make Candlestick Charts Your New Secret Weapon For Tackling Stock Analysis See All Videos NOW PLAYING Make Candlestick Charts Your New Secret Weapon For Tackling Stock Analysis Dow Jones index component Johnson & Johnson is fighting for support at its 50-day moving average as it moves closer to a 251.71 flat-base entry, according to IBD MarketSurge chart analysis. An early buy trigger is also in play at 247.21. Shares slipped 1.1% Tuesday afternoon. **J&J stock backstory**: Johnson & Johnson is a diversified medical player, making what it calls "innovative medicines" and medical products. The innovative medicines division is J&J's biggest, projected to bring in 64% of total sales in the first quarter. * * * **Unsure How To Invest In Stocks In This Market? Start Here ** * * * Non-Dow Jones Stocks To Watch: Burlington, TJX ---------------------------------------------- Two names to watch that are not part of the Dow Jones index are Burlington Stores and TJX. Shares of Burlington Stores are falling back below a 332.20 entry in a flat base amid Tuesday's 3.6% midday loss. Wait for a decisive retake before considering a new purchase of shares. **Burlington stock backstory**: Burlington could benefit from the Iran war. Supply disruptions could increase unwanted or closeout inventory among full-price retailers. That means off-price retail chains can buy it at cheaper prices. Bargain retailers can be defensive growth investments in a volatile and uncertain market. New Jersey-based Burlington Stores operates 1,212 off-price retail stores that generated $11.5 billion in 2025 sales. * * * **Internet Optimizer Getting A Handle On Cracked Market — Maybe** * * * Meanwhile, shares of TJX are just shy of their latest buy point. The flat base has a 162.68 buy point. The stock is down nearly 2% during Tuesday's trade. **TJX stock backstory: ** On Feb. 25, TJX beat earnings expectations for its fiscal fourth quarter. Comparable store sales grew 5% for both the fourth quarter and the full year. On March 30, management announced a 13% dividend increase and plans for $2.5 billion to $2.75 billion in stock buybacks. The parent of T.J. Maxx, Marshalls and Home Goods chains tied the actions to confidence in sustained profitability, strong cash flow and overall business growth. IBD Newsletters --------------- #### Get exclusive IBD analysis and actionable news daily. SIGN UP NOW! IBD Newsletters --------------- #### Get exclusive IBD analysis and actionable news daily. * How To Invest * Market Prep * Tech Report Please enter a valid email address Please select a newsletter GO Get these newsletters delivered to your inbox & more info about our products & services. Privacy Policy & Terms of Use x Thank You! ---------- #### You will now receive IBD Newsletters ALL DONE! Something Went Wrong! --------------------- #### Please contact customer service CLOSE AstraZeneca Stock Eyes Latest Buy Point --------------------------------------- Another name to watch outside the Dow Jones Industrial Average is AstraZeneca. The stock declined 1.6% Tuesday afternoon, about 5% away from a 212.71 entry in a cup base. **AstraZeneca stock backstory: **In late March, the U.K.-based drugmaker said its chronic obstructive pulmonary disease drug succeeded in two final-phase studies. AstraZeneca plans to present the full results at an upcoming medical conference. * * * **Read Between The Lines To Understand This IBD 50 Stock — And What Might Come Next** * * * Investing Tips -------------- Investor's Business Daily maintains its recommended stock exposure at 0% to 20% due to heavy losses in recent sessions. That means IBD readers should adjust their exposure by cutting losses short and remaining mostly in cash. They can add limited exposure by buying stocks with exceptional breakouts, but those are in short supply. An essential resource for daily breakouts is IBD MarketSurge's Breaking Out Today list. It shows MarketSurge Growth 250 stocks that are rising past fresh buy points. Before making any investment decisions, be sure to check current stock market conditions. Also, use IBD Stock Checkup to view ratings for the most important fundamental and technical criteria. To get chart analysis on stocks to buy and watch, as well as high-odds buy and sell alerts, check out IBD MarketSurge, IBD Leaderboard, and IBD SwingTrader. Best Stocks To Watch, Including A Dow Jones Index Leader -------------------------------------------------------- These are the best stocks to watch near buy points, including Dow leader Johnson & Johnson. | **Symbol** | | --- | **Company** | **Chart analysis** | | (JNJ) | **Johnson & Johnson** | Flat base has a 251.71 entry. | | (BURL) | **Burlington Stores** | Below buy point at 332.20. | | (TJX) | **TJX** | Nearing a 162.68 buy trigger. | | (AZN) | **AstraZeneca** | Cup base offers a 212.71 buy point. | _Follow Scott Lehtonen on X at @IBD_SLehtonen for top stocks to watch and the Dow Jones Industrial Average action._ **YOU MAY ALSO LIKE:** Top Growth Stocks To Buy And Watch Learn How To Time The Market With IBD's ETF Market Strategy Find The Best Long-Term Investments With IBD Long-Term Leaders Check Out IBD's New Exposure Levels To Help You Stay In Step With The Market Trend Spot Buy Points And Sell Signals With MarketSurge Pattern Recognition
1
0
0
0
NodeGuardian

NodeGuardian

04-06 17:11
Johnson & Johnson (JNJ) stock recently pulled back, showing a 2.09% decline, though its longer-term performance remains strong. While one valuation narrative suggests JNJ is 37.2% overvalued at $173.55, Simply Wall St's discounted cash flow model indicates an undervaluation with a fair value of $383 per share. This mixed outlook highlights the need for investors to carefully consider various scenarios and risks when evaluating JNJ.
0
0
0
0